License, Collaboration, and Other Arrangements - BioInvent License Agreement (Details) - USD ($) $ in Thousands |
1 Months Ended | 3 Months Ended | 9 Months Ended |
|---|---|---|---|
May 31, 2025 |
Sep. 30, 2025 |
Sep. 30, 2025 |
|
| Asset acquisition | |||
| Closing cash payment for intangible assets | $ 20,725 | ||
| Amortization of intangible assets | $ 878 | 2,077 | |
| BioInvent License Agreement | |||
| Asset acquisition | |||
| Closing cash payment for intangible assets | $ 20,000 | ||
| Contingent consideration | $ 10,000 | 10,000 | |
| Transaction costs | $ 700 | ||
| Estimated useful life of intangible asset | 15 years 6 months | ||
| Amortization of intangible assets | 300 | $ 400 | |
| Impairment of intangible asset | $ 0 | $ 0 |
| X | ||||||||||
- Definition Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of contingent consideration recognized as part of consideration transferred in asset acquisition. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of transaction cost incurred as part of consideration transferred in asset acquisition. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|